Skip to content
Licensed Unlicensed Requires Authentication Published by De Gruyter June 15, 2023

Laboratory response to paradigm change in hemophilia treatment

How to monitor patients simultaneously treated with emicizumab and Factor VIII concentrate?

  • Marjan Shafaati Lambert , Maria Bruzelius , Nida Mahmoud Hourani Soutari , Susanna Ranta and Jovan P. Antovic EMAIL logo

Corresponding author: Jovan P. Antovic, Coagulation & Clinical Chemistry, Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden; and Coagulation, Clinical Chemistry, Karolinska University Laboratory, Medical Diagnostics Karolinska, Karolinska University Hospital, Stockholm, Sweden, E-mail:

  1. Research funding: None declared.

  2. Author contributions: All authors have accepted responsibility for the entire content of this manuscript and approved its submission.

  3. Competing interests: The authors state no conflict of interest.

  4. Informed consent: Not applicable.

  5. Ethical approval: Not applicable: un-identified samples as a part of laboratory methods development.

  6. Data availability: Yes, with written request.


1. Franchini, M, Mannucci, PM. The more recent history of hemophilia treatment. Semin Thromb Hemost 2022;48:904–10. in Google Scholar PubMed

2. Mahlangu, JN. Bispecific antibody emicizumab for haemophilia A: a breakthrough for patients with inhibitors. BioDrugs 2018;32:561–70. in Google Scholar PubMed

3. Oldenburg, J, Mahlangu, JN, Kim, B, Schmitt, C, Callaghan, MU, Young, G, et al.. Emicizumab prophylaxis in hemophilia A with inhibitors. N Engl J Med 2017;377:809–18. in Google Scholar PubMed

4. Pipe, SW, Shima, M, Lehle, M, Shapiro, A, Chebon, S, Fukutake, K, et al.. Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study. Lancet Haematol 2019;6:e295–305. in Google Scholar PubMed

5. Schmitt, C, Adamkewicz, JI, Xu, J, Petry, C, Catalani, O, Young, G, et al.. Pharmacokinetics and pharmacodynamics of emicizumab in persons with hemophilia A with factor VIII inhibitors: HAVEN 1 study. Thromb Haemostasis 2021;121:351–60. in Google Scholar PubMed PubMed Central

6. Peyvandi, F, Kenet, G, Pekrul, I, Pruthi, RK, Ramge, P, Spannagl, M. Laboratory testing in hemophilia: impact of factor and non-factor replacement therapy on coagulation assays. J Thromb Haemostasis 2020;18:1242–55. in Google Scholar PubMed

7. Sjöström, A, Långström, S, Ranta, S, Magnusson, M, Soutari, N, Entrei, J, et al.. Laboratory measurement of emicizumab. First “real-life” experience from Karolinska University Laboratory. Abstract P003. Haemophilia 2020;26 S2:29.Search in Google Scholar

8. Bowyer, AE, Maclean, RM, Kitchen, S. The combination of emicizumab and recombinant factor VIII in plasma: which assays can we use for accurate measurement? Int J Lab Hematol 2023;45:368–76. in Google Scholar PubMed

9. Bravo, MI, Raventós, A, Pérez, A, Costa, M, Willis, T. Non-additive effect on thrombin generation when a plasma-derived factor VIII/von Willebrand factor (FVIII/VWF) is combined with emicizumab in vitro. J Thromb Haemostasis 2020;18:1934–9. in Google Scholar PubMed

10. Yamaguchi, T, Shinozawa, K, Nagatoishi, S, Mitsuhashi, A, Bingo, M, Inaba, H, et al.. In vitro validation of chromogenic substrate assay for evaluation of surrogate FVIII-activity of emicizumab. Thromb Res 2023;222:131–9. in Google Scholar PubMed

11. Müller, J, Pekrul, I, Pötzsch, B, Berning, B, Oldenburg, J, Spannagl, M. Laboratory monitoring in emicizumab-treated persons with hemophilia A. Thromb Haemostasis 2019;119:1384–93. in Google Scholar PubMed

Received: 2023-05-03
Accepted: 2023-05-24
Published Online: 2023-06-15
Published in Print: 2023-11-27

© 2023 Walter de Gruyter GmbH, Berlin/Boston

Downloaded on 4.3.2024 from
Scroll to top button